Relation of aldosterone “escape” despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

This publication has 26 references indexed in Scilit:

• Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
  Circulation, 2000
• Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure
  Published by Oxford University Press (OUP) ,2000
• Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study
  European Journal of Heart Failure, 1999
• How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
  Heart, 1999
• Left atrial filling volume can be used to reliably estimate the regurgitant volume in mitral regurgitation
  Journal of the American College of Cardiology, 1999
• Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia
  Circulation, 1997
• Clinical Correlates and Prognostic Significance of the Ventilatory Response to Exercise in Chronic Heart Failure
  Journal of the American College of Cardiology, 1997
• ?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
  Cardiovascular Drugs and Therapy, 1995
• Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry
  The American Journal of Clinical Nutrition, 1990
• Captopril in heart failure. A double blind controlled trial.
  Heart, 1984